Cardiovascular Pharmacology: Current Therapies and Frontier Developments

This chapter provides an updated synthesis of pharmacological strategies in the management of heart failure, coronary artery disease, dysrhythmias, and thromboembolic disorders, incorporating the latest evidence from landmark clinical trials. It reviews novel drug classes including SGLT2 inhibitors, sacubitril-valsartan combinations, and RNA-targeted lipid-lowering therapies, and examines their mechanistic basis and evolving clinical indications.